Condition: Progressive Pulmonary Fibrosis · Idiopathic Pulmonary Fibrosis (IPF) · Sponsor: Avalyn Pharma Inc.
This is an open-label extension study for participants who were previously enrolled in and completed an Avalyn Pharma Sponsored study with an inhaled antifibrotic, such as AP01. Eligible participants will have their final dose of drug at the end of study visit from the lead-in study and first AP-LTE-008 study visit on the same day.
This description comes directly from the study's public registry record.
Dr. Felix Woodhead, MB BChir,PhD · +44 7999 885973 · fwoodhead@avalynpharma.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| University of Southern California | Los Angeles, California, United States | Recruiting |
| University of Colorado, Anschutz Medical Campus | Aurora, Colorado, United States | Recruiting |
| Renstar Medical Research | Ocala, Florida, United States | Recruiting |
| Piedmont Healthcare, Inc. | Atlanta, Georgia, United States | Recruiting |
| The University of Kansas Medical Center | Kansas City, Kansas, United States | Recruiting |
| University of Maryland | Baltimore, Maryland, United States | Recruiting |
| Johns Hopkins Asthma and Allergy Center | Baltimore, Maryland, United States | Recruiting |
| Mayo Clinic Rochester | Rochester, Minnesota, United States | Recruiting |
| Hannibal Regional Healthcare System, Inc. | Hannibal, Missouri, United States | Recruiting |
| Icahn School of Medicine at Mount Sinai | New York, New York, United States | Recruiting |
| Columbia University | New York, New York, United States | Recruiting |
+ 42 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06951217